Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo Q3

This article was originally published in The Tan Sheet

Executive Summary

Consumer Healthcare sales for the third quarter of fiscal 2006 (ended March 25) were up nearly 10% to $241.2 mil. compared to $219.7 mil. a year ago, Perrigo announces April 27. The increase occurred despite a $26 mil. decrease in sales of cough/cold products containing pseudoephedrine. The impact of pseudoephedrine declines was offset by the addition of topical product sales of $16 mil. from the recently acquired Israeli firm Agis. Effects from lower cough/cold sales also were offset by new product gains in smoking cessation and higher vitamin sales, Perrigo states. "Because of the new products, fourth quarter profitability should be in line with historical levels despite increased costs for the large number of cough/cold product reformulations," Perrigo Chairman, President and CEO David Gibbons stated. Net sales for the third quarter were up 51% to $332.3 mil. from $220.1 mil. last year...

You may also be interested in...

Regeneron COVID-19 Cocktail’s Flame To Burn Brightly But Unclear For How Long

Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.

Manufacturers Want Delay In Conducting US Nitrosamine Risk Assessments

Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.

Merck & Co. Buys Out OncoImmune For Phase III COVID-19 Therapy

Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts